Analysis of adverse events of bevacizumab-containing systemic chemotherapy for metastatic colorectal cancer in Japan
T Isobe, K Uchino, C Makiyama, H Ariyama… - Anticancer …, 2014 - ar.iiarjournals.org
Background: Bevacizumab (BV) is widely used in chemotherapy for metastatic colorectal
cancer (mCRC). Although specific adverse events have been observed, their risk factors …
cancer (mCRC). Although specific adverse events have been observed, their risk factors …
Analysis of adverse events of bevacizumab-containing systemic chemotherapy for metastatic colorectal cancer in Japan
T Isobe, K Uchino, C Makiyama, H Ariyama… - Anticancer …, 2014 - hero.epa.gov
BACKGROUND: Bevacizumab (BV) is widely used in chemotherapy for metastatic colorectal
cancer (mCRC). Although specific adverse events have been observed, their risk factors …
cancer (mCRC). Although specific adverse events have been observed, their risk factors …
Analysis of adverse events of bevacizumab-containing systemic chemotherapy for metastatic colorectal cancer in Japan
T Isobe, K Uchino, C Makiyama… - Anticancer …, 2014 - pubmed.ncbi.nlm.nih.gov
Background Bevacizumab (BV) is widely used in chemotherapy for metastatic colorectal
cancer (mCRC). Although specific adverse events have been observed, their risk factors …
cancer (mCRC). Although specific adverse events have been observed, their risk factors …
Analysis of adverse events of bevacizumab-containing systemic chemotherapy for metastatic colorectal cancer in Japan
T Isobe, K Uchino, C Makiyama… - Anticancer …, 2014 - kyushu-u.pure.elsevier.com
Background: Bevacizumab (BV) is widely used in chemotherapy for metastatic colorectal
cancer (mCRC). Although specific adverse events have been observed, their risk factors …
cancer (mCRC). Although specific adverse events have been observed, their risk factors …
[PDF][PDF] Analysis of Adverse Events of Bevacizumab-containing Systemic Chemotherapy for Metastatic Colorectal Cancer in Japan
T ISOBE, K UCHINO, C MAKIYAMA… - ANTICANCER …, 2014 - ar.iiarjournals.org
Background: Bevacizumab (BV) is widely used in chemotherapy for metastatic colorectal
cancer (mCRC). Although specific adverse events have been observed, their risk factors …
cancer (mCRC). Although specific adverse events have been observed, their risk factors …
Analysis of adverse events of bevacizumab-containing systemic chemotherapy for metastatic colorectal cancer in Japan
T Isobe, K Uchino, C Makiyama… - Anticancer …, 2014 - kyushu-u.elsevierpure.com
Background: Bevacizumab (BV) is widely used in chemotherapy for metastatic colorectal
cancer (mCRC). Although specific adverse events have been observed, their risk factors …
cancer (mCRC). Although specific adverse events have been observed, their risk factors …
Analysis of adverse events of bevacizumab-containing systemic chemotherapy for metastatic colorectal cancer in Japan.
T Isobe, K Uchino, C Makiyama, H Ariyama… - Anticancer …, 2014 - europepmc.org
Analysis of adverse events of bevacizumab-containing systemic chemotherapy for metastatic
colorectal cancer in Japan. - Abstract - Europe PMC Sign in | Create an account https://orcid.org …
colorectal cancer in Japan. - Abstract - Europe PMC Sign in | Create an account https://orcid.org …